JP2018508188A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018508188A5 JP2018508188A5 JP2017536356A JP2017536356A JP2018508188A5 JP 2018508188 A5 JP2018508188 A5 JP 2018508188A5 JP 2017536356 A JP2017536356 A JP 2017536356A JP 2017536356 A JP2017536356 A JP 2017536356A JP 2018508188 A5 JP2018508188 A5 JP 2018508188A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- region
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021038857A JP7177317B2 (ja) | 2015-01-08 | 2021-03-11 | Ｃｄ３およびｃｄ２０に対する二重特異性抗体 |
| JP2022162493A JP7596342B2 (ja) | 2015-01-08 | 2022-10-07 | Ｃｄ３およびｃｄ２０に対する二重特異性抗体 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2015/050276 WO2015104346A1 (en) | 2014-01-09 | 2015-01-08 | Humanized or chimeric cd3 antibodies |
| EPPCT/EP2015/050276 | 2015-01-08 | ||
| DKPA201500413 | 2015-07-15 | ||
| DKPA201500412 | 2015-07-15 | ||
| DKPA201500412 | 2015-07-15 | ||
| DKPA201500413 | 2015-07-15 | ||
| DKPA201500415 | 2015-07-16 | ||
| DKPA201500416 | 2015-07-16 | ||
| DKPA201500416 | 2015-07-16 | ||
| DKPA201500415 | 2015-07-16 | ||
| PCT/EP2016/050296 WO2016110576A1 (en) | 2015-01-08 | 2016-01-08 | Bispecific antibodies against cd3 and cd20 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021038857A Division JP7177317B2 (ja) | 2015-01-08 | 2021-03-11 | Ｃｄ３およびｃｄ２０に対する二重特異性抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018508188A JP2018508188A (ja) | 2018-03-29 |
| JP2018508188A5 true JP2018508188A5 (enExample) | 2019-02-14 |
| JP6853176B2 JP6853176B2 (ja) | 2021-03-31 |
Family
ID=56355550
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017536356A Active JP6853176B2 (ja) | 2015-01-08 | 2016-01-08 | Ｃｄ３およびｃｄ２０に対する二重特異性抗体 |
| JP2021038857A Active JP7177317B2 (ja) | 2015-01-08 | 2021-03-11 | Ｃｄ３およびｃｄ２０に対する二重特異性抗体 |
| JP2022162493A Active JP7596342B2 (ja) | 2015-01-08 | 2022-10-07 | Ｃｄ３およびｃｄ２０に対する二重特異性抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021038857A Active JP7177317B2 (ja) | 2015-01-08 | 2021-03-11 | Ｃｄ３およびｃｄ２０に対する二重特異性抗体 |
| JP2022162493A Active JP7596342B2 (ja) | 2015-01-08 | 2022-10-07 | Ｃｄ３およびｃｄ２０に対する二重特異性抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10544220B2 (enExample) |
| EP (2) | EP4678661A3 (enExample) |
| JP (3) | JP6853176B2 (enExample) |
| KR (3) | KR20240148942A (enExample) |
| CN (2) | CN114478792A (enExample) |
| AU (3) | AU2016205967B2 (enExample) |
| CA (1) | CA2973159A1 (enExample) |
| EA (1) | EA201791554A1 (enExample) |
| IL (3) | IL318350A (enExample) |
| MX (2) | MX391279B (enExample) |
| SG (1) | SG11201705496SA (enExample) |
| UA (1) | UA120286C2 (enExample) |
| WO (1) | WO2016110576A1 (enExample) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3434767T (pt) * | 2010-11-30 | 2026-01-23 | Chugai Pharmaceutical Co Ltd | Agente terapêutico indutor de citotoxicidade |
| CN104736174B (zh) | 2012-07-06 | 2019-06-14 | 根马布私人有限公司 | 具有三重突变的二聚体蛋白质 |
| ME03675B (me) | 2013-07-05 | 2020-10-20 | Genmab As | Humanizovana ili himerna anтi-cd3 antiтela |
| IL263466B2 (en) | 2013-12-17 | 2023-10-01 | Genentech Inc | Anti-CD3 antibodies and methods of using them |
| MA40579A (fr) | 2014-09-12 | 2016-03-17 | Genentech Inc | Anticorps anti-cll-1 et immunoconjugués |
| DK3310814T5 (da) | 2015-06-16 | 2024-10-07 | Hoffmann La Roche | Humaniserede og affinitetsmodnede antistoffer mod FcRH5 og fremgangsmåder til anvendelse |
| US10501545B2 (en) | 2015-06-16 | 2019-12-10 | Genentech, Inc. | Anti-CLL-1 antibodies and methods of use |
| EP3916018A1 (en) | 2015-06-16 | 2021-12-01 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| IL256562B2 (en) | 2015-07-15 | 2024-07-01 | Genmab As | Human CD3 antibodies or chimeras |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| EP3252078A1 (en) * | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
| WO2018220099A1 (en) * | 2017-06-02 | 2018-12-06 | F. Hoffmann-La Roche Ag | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
| EP3904880A1 (fr) * | 2016-09-30 | 2021-11-03 | Centre national de la recherche scientifique | Marqueurs membranaires |
| JP7784795B2 (ja) * | 2016-11-15 | 2025-12-12 | ジェネンテック， インコーポレイテッド | 抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与 |
| KR102692708B1 (ko) * | 2016-12-20 | 2024-08-07 | 에프. 호프만-라 로슈 아게 | 항-cd20/항-cd3 이중특이성 항체 및 4-1bb(cd137) 작용물질의 병용 요법 |
| CN108395482B (zh) | 2017-02-08 | 2021-02-05 | 西比曼生物科技（香港）有限公司 | 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定 |
| KR102794369B1 (ko) | 2017-08-01 | 2025-04-15 | 에이비 테라퓨틱스 인코퍼레이티드 | 이중특이 항체 및 그의 용도 |
| SG11202000198QA (en) | 2017-08-04 | 2020-02-27 | Genmab As | Binding agents binding to pd-l1 and cd137 and use thereof |
| WO2019034580A1 (en) * | 2017-08-14 | 2019-02-21 | Morphosys Ag | HUMANIZED ANTIBODIES FOR CD3 |
| CN107501412A (zh) * | 2017-10-11 | 2017-12-22 | 深圳精准医疗科技有限公司 | 突变型双特异性抗体及其应用 |
| IL325995A (en) | 2018-02-08 | 2026-03-01 | Genentech Inc | Bispecific antigen binding molecules and methods of use |
| CN111787948A (zh) * | 2018-02-09 | 2020-10-16 | 健玛保 | 包含针对cd3和cd20的双特异性抗体的药物组合物及其用途 |
| CN120399075A (zh) | 2018-03-14 | 2025-08-01 | 诺维莫尼公司 | 抗-CD3ε抗体及其应用方法 |
| EP3569617A1 (en) * | 2018-05-18 | 2019-11-20 | Trion Research GmbH | Pharmaceutical preparation for use in treating epstein- barr virus positive patients with reactivation phenomenon- associated diseases |
| CN110540593B (zh) * | 2018-05-29 | 2022-05-17 | 上海药明生物技术有限公司 | 新型的抗cd3/抗cd20双特异性抗体 |
| TW202016144A (zh) * | 2018-06-21 | 2020-05-01 | 日商第一三共股份有限公司 | 包括cd3抗原結合片段之組成物及其用途 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CN109836502B (zh) * | 2018-11-12 | 2021-09-07 | 浙江大学 | 一种双特异性抗体及其应用 |
| US12463463B2 (en) | 2019-01-28 | 2025-11-04 | Ab Therapeutics, Inc. | Bispecific antibodies and uses thereof |
| CN112703013B (zh) * | 2019-02-22 | 2022-09-30 | 武汉友芝友生物制药股份有限公司 | Cd3抗原结合片段及其应用 |
| WO2020229378A1 (en) * | 2019-05-13 | 2020-11-19 | F. Hoffmann-La Roche Ag | Interference-suppressed pharmacokinetic immunoassay |
| CN110551221B (zh) * | 2019-07-02 | 2021-03-05 | 广州爱思迈生物医药科技有限公司 | 一种双特异性抗体及其制备方法与应用 |
| JP7656587B2 (ja) * | 2019-08-15 | 2025-04-03 | ジェンマブ エー／エス | Ｃｄ３およびｃｄ２０に対する二重特異性抗体を含む薬学的組成物、ならびにそれらの使用 |
| CN111100204B (zh) * | 2019-11-26 | 2022-03-11 | 山东立菲生物产业有限公司 | 靶向cd20的抗体、其制备方法和应用 |
| WO2021119505A1 (en) | 2019-12-13 | 2021-06-17 | Genentech, Inc. | Anti-ly6g6d antibodies and methods of use |
| WO2021144315A1 (en) * | 2020-01-13 | 2021-07-22 | Synaffix B.V. | Conjugates of antibodies an immune cell engagers |
| CN113402612A (zh) * | 2020-03-17 | 2021-09-17 | 西比曼生物科技（香港）有限公司 | 靶向cd19和cd20的联合嵌合抗原受体及其应用 |
| MX2022009936A (es) * | 2020-03-18 | 2022-09-12 | Genmab As | Anticuerpos que se unen al dominio v-set que contiene el inhibidor de activacion de celulas t 1 (b7h4). |
| MX2022013797A (es) | 2020-05-08 | 2022-11-30 | Genmab As | Anticuerpos biespecificos contra cd3 y cd20. |
| US10981996B1 (en) * | 2020-06-01 | 2021-04-20 | Abexxa Biologics, Inc. | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
| US11976120B2 (en) * | 2020-06-01 | 2024-05-07 | Boehringer Ingelheim International Gmbh | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
| CN112062855B (zh) * | 2020-08-26 | 2024-08-30 | 北京天诺健成医药科技有限公司 | 一种含有衔接器的药物治疗剂的开发和应用 |
| CA3189883A1 (en) | 2020-09-10 | 2022-03-17 | Brian Elliott | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma |
| CA3190376A1 (en) | 2020-09-10 | 2022-03-17 | Brian Elliott | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma |
| EP4210745A1 (en) * | 2020-09-10 | 2023-07-19 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
| US20240034812A1 (en) * | 2020-09-10 | 2024-02-01 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
| CN116782933A (zh) * | 2020-09-10 | 2023-09-19 | 健玛保 | 用于治疗弥漫性大b细胞淋巴瘤的联合疗法中的针对cd3和cd20的双特异性抗体 |
| KR20230066040A (ko) | 2020-09-10 | 2023-05-12 | 젠맵 에이/에스 | 만성 림프구성 백혈병을 치료하기 위한 cd3 및 cd20에 대한 이중특이적 항체 |
| TWI874719B (zh) | 2020-11-04 | 2025-03-01 | 美商建南德克公司 | 用抗cd20/抗cd3雙特異性抗體進行治療之給藥 |
| AU2021374594B2 (en) | 2020-11-04 | 2026-03-05 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates |
| JP7716473B2 (ja) | 2020-11-04 | 2025-07-31 | ジェネンテック， インコーポレイテッド | 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬 |
| CN114656562B (zh) * | 2020-12-23 | 2023-11-03 | 北京天广实生物技术股份有限公司 | 结合人和猴cd3的抗体及其应用 |
| AU2022214319A1 (en) | 2021-01-28 | 2023-08-03 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for treating cytokine release syndrome |
| WO2022192895A1 (en) * | 2021-03-10 | 2022-09-15 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Compositions and methods to reduce therapeutic t cell toxicity |
| MX2023010567A (es) * | 2021-03-12 | 2023-09-21 | Genmab As | Variantes de anticuerpos no activadoras. |
| CA3213632A1 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
| EP4337330A1 (en) | 2021-05-14 | 2024-03-20 | Genentech, Inc. | Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin |
| MX2024008833A (es) | 2022-01-28 | 2024-07-25 | Genmab As | Anticuerpo biespecifico contra cumulo de diferenciacion 3 (cd3) y cumulo de diferenciacion 20 (cd20) en terapia combinada para tratar linfoma difuso de celulas b grandes. |
| CN118647402A (zh) | 2022-01-28 | 2024-09-13 | 健玛保 | 用于治疗弥漫性大b细胞淋巴瘤的联合疗法中的针对cd3和cd20的双特异性抗体 |
| EP4507790A1 (en) | 2022-04-11 | 2025-02-19 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| US11958906B2 (en) | 2022-04-13 | 2024-04-16 | Genentech, Inc. | Pharmaceutical compositions of mosunetuzumab and methods of use |
| US20250304689A1 (en) | 2022-04-13 | 2025-10-02 | Genmab A/S | Bispecific antibodies against cd3 and cd20 |
| WO2024102948A1 (en) | 2022-11-11 | 2024-05-16 | Celgene Corporation | Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods |
| IL321437A (en) * | 2022-12-14 | 2025-08-01 | Evolveimmune Therapeutics Inc | Bispecific antibody fusion molecules and methods for using them |
| CN120857940A (zh) | 2023-02-17 | 2025-10-28 | 瑞泽恩制药公司 | 对cd3/taa双特异性抗体有反应的诱导型nk细胞 |
| KR20250131823A (ko) | 2023-03-31 | 2025-09-03 | 아벨제타 인크. | Cd20 및 bcma를 표적화하는 이중특이적 키메라 항원 수용체 |
| CN121311504A (zh) | 2023-04-13 | 2026-01-09 | 金麦安博股份有限公司 | 用针对cd3和cd20的双特异性抗体治疗淋巴瘤的方法 |
| WO2024236031A1 (en) | 2023-05-15 | 2024-11-21 | Genmab A/S | Highly purified epcoritamab compositions |
| US20240409656A1 (en) | 2023-05-15 | 2024-12-12 | Genmab A/S | Methods of treating cd20 expressing b-cell cancers |
| WO2025064890A1 (en) * | 2023-09-20 | 2025-03-27 | Evolveimmune Therapeutics, Inc. | Bispecific antibody fusion molecules targeting cd180 and cd3 and methods of use thereof |
| WO2025109119A1 (en) * | 2023-11-22 | 2025-05-30 | Priothera Sas | Methods of treatment with multispecific antigen-binding proteins in combination with s1p receptor modulators |
| GB2641580A (en) | 2024-06-07 | 2025-12-10 | T Therapeutics Ltd | Tumour-transforming multispecific proteins |
| WO2026078231A1 (en) | 2024-10-11 | 2026-04-16 | T-Therapeutics Limited | Soluble non-aggregating immune ligand |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6077A (en) | 1849-01-30 | Improved hinged claw-wrench | ||
| US835A (en) | 1838-07-12 | X i i i x | ||
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| ATE299938T1 (de) | 1997-05-02 | 2005-08-15 | Genentech Inc | Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
| EP1068296B1 (en) | 1998-03-31 | 2011-08-10 | Geron Corporation | Compositions for eliciting an immune response to a telomerase antigen |
| WO2000046147A2 (en) | 1999-02-03 | 2000-08-10 | Biosante Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of manufacture and use |
| US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
| AU2002235141A1 (en) | 2000-11-27 | 2002-06-03 | Geron Corporation | Glycosyltransferase vectors for treating cancer |
| US20100081792A1 (en) | 2001-06-28 | 2010-04-01 | Smithkline Beecham Corporation | Ligand |
| JP2006502091A (ja) | 2002-03-01 | 2006-01-19 | イミューノメディクス、インコーポレイテッド | クリアランス速度を高めるための二重特異性抗体点変異 |
| DK2314629T4 (da) | 2002-07-18 | 2023-02-06 | Merus Nv | Rekombinant produktion af blandinger af antistoffer |
| BRPI0315295C1 (pt) * | 2002-10-17 | 2021-05-25 | Genmab As | anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão |
| KR20060041205A (ko) | 2003-07-01 | 2006-05-11 | 이뮤노메딕스, 인코오포레이티드 | 양특이성 항체들의 다가 담체들 |
| US9296820B2 (en) | 2003-11-05 | 2016-03-29 | Roche Glycart Ag | Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function |
| US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| US7741568B2 (en) | 2005-01-13 | 2010-06-22 | The Wiremold Company | Downward facing receptacle assembly for cable raceway |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP1940881B1 (en) * | 2005-10-11 | 2016-11-30 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
| CA2631184A1 (en) | 2005-11-28 | 2007-05-31 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| CA2646508A1 (en) | 2006-03-17 | 2007-09-27 | Biogen Idec Ma Inc. | Stabilized polypeptide compositions |
| PT1999154E (pt) | 2006-03-24 | 2013-01-24 | Merck Patent Gmbh | Domínios proteicos heterodiméricos modificados |
| AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
| ES2593484T3 (es) | 2007-03-29 | 2016-12-09 | Genmab A/S | Anticuerpos biespecíficos y métodos de producción de los mismos |
| RS53008B2 (sr) | 2007-04-03 | 2022-12-30 | Amgen Res Munich Gmbh | Interspecijski specifičan cd3-epsilon vezujući domen |
| WO2008145141A1 (en) * | 2007-05-31 | 2008-12-04 | Genmab A/S | Method for extending the half-life of exogenous or endogenous soluble molecules |
| JP5511654B2 (ja) * | 2007-05-31 | 2014-06-04 | ゲンマブ エー／エス | 分子操作により得られた組換え非グリコシル化一価半抗体 |
| WO2008145140A2 (en) * | 2007-05-31 | 2008-12-04 | Genmab A/S | Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals |
| EP2158221B1 (en) | 2007-06-21 | 2018-08-29 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| EP2535349A1 (en) | 2007-09-26 | 2012-12-19 | UCB Pharma S.A. | Dual specificity antibody fusions |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| JP6157046B2 (ja) | 2008-01-07 | 2017-07-05 | アムジェン インコーポレイテッド | 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法 |
| WO2010015792A1 (en) | 2008-08-06 | 2010-02-11 | Argenta Discovery Limited | Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors |
| EP2352765B1 (en) * | 2008-10-01 | 2018-01-03 | Amgen Research (Munich) GmbH | Cross-species-specific single domain bispecific single chain antibody |
| WO2010059315A1 (en) | 2008-11-18 | 2010-05-27 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
| DK2786762T3 (da) | 2008-12-19 | 2019-05-06 | Macrogenics Inc | Kovalente diabodies og anvendelser deraf |
| WO2010111625A1 (en) | 2009-03-27 | 2010-09-30 | Zymogenetics, Inc. | Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination |
| WO2010129304A2 (en) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| KR101224468B1 (ko) | 2009-05-20 | 2013-01-23 | 주식회사 파멥신 | 신규한 형태의 이중표적항체 및 그 용도 |
| UY32808A (es) | 2009-07-29 | 2011-02-28 | Abbott Lab | Inmunoglobulinas como dominio variable dual y usos de las mismas |
| WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| US8961967B2 (en) | 2009-11-30 | 2015-02-24 | Janssen Biotech, Inc. | Antibody Fc mutants with ablated effector functions |
| CN102770456B (zh) | 2009-12-04 | 2018-04-06 | 弗·哈夫曼-拉罗切有限公司 | 多特异性抗体、抗体类似物、组合物和方法 |
| CA2785907A1 (en) | 2009-12-29 | 2011-07-28 | Emergent Product Development Seattle, Llc | Ron binding constructs and methods of use thereof |
| AR080794A1 (es) | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
| HRP20241208T1 (hr) * | 2010-04-20 | 2024-11-22 | Genmab A/S | Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju |
| US9527926B2 (en) | 2010-05-14 | 2016-12-27 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
| CN103261220B (zh) | 2010-08-16 | 2016-06-15 | 诺夫免疫股份有限公司 | 用于生成多特异性和多价抗体的方法 |
| CN103068847B (zh) | 2010-08-24 | 2019-05-07 | 罗切格利卡特公司 | 可活化的双特异性抗体 |
| CN103068846B9 (zh) | 2010-08-24 | 2016-09-28 | 弗·哈夫曼-拉罗切有限公司 | 包含二硫键稳定性Fv片段的双特异性抗体 |
| ES2758994T3 (es) | 2010-11-05 | 2020-05-07 | Zymeworks Inc | Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc |
| PT3434767T (pt) * | 2010-11-30 | 2026-01-23 | Chugai Pharmaceutical Co Ltd | Agente terapêutico indutor de citotoxicidade |
| AU2012245116A1 (en) * | 2011-04-20 | 2013-11-07 | Genmab A/S | Bispecific antibodies against HER2 and CD3 |
| KR102060389B1 (ko) * | 2011-05-21 | 2019-12-31 | 마크로제닉스, 인크. | 사람 및 비-사람 cd3에 결합할 수 있는 cd3-결합 분자 |
| CN102250246A (zh) | 2011-06-10 | 2011-11-23 | 常州亚当生物技术有限公司 | 抗VEGF/PDGFRβ双特异性抗体及其应用 |
| NO2748201T3 (enExample) | 2011-08-23 | 2018-05-12 | ||
| SG11201401422VA (en) | 2011-10-27 | 2014-09-26 | Genmab As | Production of heterodimeric proteins |
| US9248181B2 (en) | 2012-04-20 | 2016-02-02 | Merus B.V. | Methods and means for the production of Ig-like molecules |
| CN104736174B (zh) | 2012-07-06 | 2019-06-14 | 根马布私人有限公司 | 具有三重突变的二聚体蛋白质 |
| JOP20200236A1 (ar) * | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| DK2924052T3 (da) | 2012-11-21 | 2019-09-30 | Pharmabcine Inc | Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme |
| EP2961773B1 (en) | 2013-02-26 | 2019-03-20 | Roche Glycart AG | Bispecific t cell activating antigen binding molecules |
| EP2961770A1 (en) | 2013-02-26 | 2016-01-06 | Roche Glycart AG | Bispecific t cell activating antigen binding molecules |
| ME03675B (me) | 2013-07-05 | 2020-10-20 | Genmab As | Humanizovana ili himerna anтi-cd3 antiтela |
| WO2015006749A2 (en) * | 2013-07-12 | 2015-01-15 | Zymeworks Inc. | Bispecific cd3 and cd19 antigen binding contructs |
| IL263466B2 (en) * | 2013-12-17 | 2023-10-01 | Genentech Inc | Anti-CD3 antibodies and methods of using them |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| KR102614189B1 (ko) | 2014-11-17 | 2023-12-18 | 리제너론 파아마슈티컬스, 인크. | Cd3xcd20 이특이적 항체를 이용한 종양의 치료 방법 |
| WO2017210485A1 (en) | 2016-06-01 | 2017-12-07 | Xencor, Inc. | Bispecific antibodies that bind cd20 and cd3 for use in the treatment of lymphoma |
| WO2019034580A1 (en) * | 2017-08-14 | 2019-02-21 | Morphosys Ag | HUMANIZED ANTIBODIES FOR CD3 |
| CA3189883A1 (en) * | 2020-09-10 | 2022-03-17 | Brian Elliott | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma |
-
2016
- 2016-01-08 US US15/541,594 patent/US10544220B2/en active Active
- 2016-01-08 IL IL318350A patent/IL318350A/en unknown
- 2016-01-08 SG SG11201705496SA patent/SG11201705496SA/en unknown
- 2016-01-08 KR KR1020247032341A patent/KR20240148942A/ko active Pending
- 2016-01-08 JP JP2017536356A patent/JP6853176B2/ja active Active
- 2016-01-08 WO PCT/EP2016/050296 patent/WO2016110576A1/en not_active Ceased
- 2016-01-08 CA CA2973159A patent/CA2973159A1/en active Pending
- 2016-01-08 IL IL289946A patent/IL289946B2/en unknown
- 2016-01-08 UA UAA201708112A patent/UA120286C2/uk unknown
- 2016-01-08 EP EP25189898.7A patent/EP4678661A3/en active Pending
- 2016-01-08 MX MX2017008875A patent/MX391279B/es unknown
- 2016-01-08 EP EP16700133.8A patent/EP3242682A1/en not_active Withdrawn
- 2016-01-08 CN CN202210117824.1A patent/CN114478792A/zh active Pending
- 2016-01-08 AU AU2016205967A patent/AU2016205967B2/en active Active
- 2016-01-08 KR KR1020247014333A patent/KR102712786B1/ko active Active
- 2016-01-08 EA EA201791554A patent/EA201791554A1/ru unknown
- 2016-01-08 KR KR1020177021738A patent/KR102663073B1/ko active Active
- 2016-01-08 CN CN201680014755.4A patent/CN107660214B/zh active Active
-
2017
- 2017-06-25 IL IL253166A patent/IL253166B/en unknown
- 2017-07-04 MX MX2022004082A patent/MX2022004082A/es unknown
-
2019
- 2019-12-04 US US16/702,996 patent/US20200199231A1/en active Pending
-
2021
- 2021-03-11 JP JP2021038857A patent/JP7177317B2/ja active Active
-
2022
- 2022-02-10 AU AU2022200871A patent/AU2022200871B2/en active Active
- 2022-10-07 JP JP2022162493A patent/JP7596342B2/ja active Active
-
2025
- 2025-08-07 AU AU2025213616A patent/AU2025213616A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018508188A5 (enExample) | ||
| US10899842B2 (en) | 4-1BB binding proteins and uses thereof | |
| TWI508745B (zh) | ＴＮＦ－α結合蛋白 | |
| US8877194B2 (en) | TNF-α binding proteins | |
| CN102906113B (zh) | 治疗性dll4结合蛋白 | |
| JP2023002615A5 (enExample) | ||
| JP2023538945A5 (enExample) | ||
| JP2016529882A5 (enExample) | ||
| JP2018183173A5 (enExample) | ||
| FI3322727T3 (fi) | Humanisoituja tai kimeerisiä CD3-vasta-aineita | |
| EP3634998B1 (en) | Anti-cd3 epsilon antibodies | |
| WO2014089209A2 (en) | Blood-brain barrier (bbb) penetrating dual specific binding proteins | |
| CN102655880A (zh) | Il-1结合蛋白 | |
| JP2018531219A6 (ja) | Ｐｄ−ｌ１抗体 | |
| JP2018531219A (ja) | Ｐｄ−ｌ１抗体 | |
| KR20110040886A (ko) | 프로스타글란딘 ｅ2 결합 단백질 및 이의 용도 | |
| KR20110110349A (ko) | Ｉｌ-1 결합 단백질 | |
| EP2970457A2 (en) | Dual specific binding proteins directed against tnf | |
| TW201307388A (zh) | Ｉｌ－１結合蛋白 | |
| WO2013157105A1 (ja) | ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用 | |
| JP2017507131A5 (enExample) | ||
| RU2005121669A (ru) | Анти-nogo антитела ("11с7") и их фармацевтическое использование | |
| AU2024255174A1 (en) | Methods of treating lymphoma with bispecific antibodies against cd3 and cd20 | |
| KR20260062948A (ko) | Ctla4/tigit 결합 단백질 및 이의 의학적 용도 | |
| WO2022238459A1 (en) | New humanized anti-vegfc antibodies and uses thereof |